Litcius/Paper detail

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

Yann Nguyen, Adrien Flahault, Nathalie Chavarot, Cléa Melenotte, Morgane Cheminant, P Deschamps, Nicolas Carlier, Emmanuel Lafont, M. Thomas, Edouard Flamarion, David Lebeaux, Caroline Charlier, A. Rachline, Corinne Guérin, Robert Ratiney, J Touchard, Hélène Péré, Flore Rozenberg, Fanny Lanternier, Jean‐Benoît Arlet, Jérôme Avouac, Véronique Boussaud, R. Guillemain, Marguerite Vignon, Éric Thervet, Anne Scemla, Laurence Weiss, Luc Mouthon

2022Clinical Microbiology and Infection109 citationsDOIOpen Access PDF

Topics & Concepts

MedicineIncidence (geometry)Coronavirus disease 2019 (COVID-19)Internal medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CohortObservational studyCohort studyRetrospective cohort studyPediatricsOpticsPhysicsInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients | Litcius